evidence: In clinical trials assessing the safety of RSV vaccines in adults ages 60 years and older, the frequency of serious adverse events (SAEs) was similar in the vaccinated group compared to the placebo (control, or unvaccinated) group. Among adults ages 60 years and older receiving GSK (Arexvy) and Pfizer (Abrysvo) RSV vaccines, a small number of people developed serious neurologic conditions, such as Guillain-Barré syndrome (GBS), within 42 days after vaccination. Given the small number, it was unclear if the vaccines caused these events or if they occurred due to chance. Among adults ages 60 years and older receiving the Moderna RSV vaccine (mResvia), there were no reported cases of GBS within 42 days after vaccination. [...] - Advisory Committee on Immunization Practices (ACIP). ACIP Presentation Slides: September 22, 2023 Meeting. https://www.cdc.gov/vaccines/acip/meetings/slides-2023-09-22.html - Hause AM, Moro PL, Baggs J, et al. Early Safety Findings Among Persons Aged ≥60 Years Who Received a Respiratory Syncytial Virus Vaccine — United States, May 3, 2023–April 14, 2024. MMWR Morb Mortal Wkly Rep 2024;73:489–494.